Background The latest changes in racial and geographical enrollment in cancer clinical trials in the 2020s have not been fully characterized, despite ongoing measures by the US Food and Drug Administration (FDA) to enhance diversity. We aimed to quantitatively elucidate the trial population of FDA-approved cancer drugs...
Meta-analyses of survival outcomes commonly pool log hazard ratios or survival probabilities at selected time points. When reporting formats and observation times differ across studies, methods are needed to use available survival information for estimation at a common target time. We propose a functional random-effect...
Randomized controlled trials remain the benchmark for estimating treatment effects, yet practical constraints often restrict sample sizes in a prespecified target population. In such settings, evidence from completed trials is frequently available only in aggregate form, which precludes direct individual-level integrat...
Keisuke Hanada, M. Kojima· Biometrical journal. Biometr...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.